SCHEMBL3702216

SCHEMBL3702216

Oc1ccnc2ccc(OC(F)(F)F)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4C Q9H3R0 1/20 0.42
DHODH Q02127 1/20 0.41
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 2/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236189 0.81 SMN1; SMN2 (0.55) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL30880730 0.81 TRPV1 (0.43) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL21101291 0.81 AAK1 (0.42) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL2209996 0.81 TRPV1 (0.43) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL16289934 0.81 NPC1 (0.41) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL4271192 0.81 NR4A2 (0.51) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL5516674 0.81 LMNA (0.43) HTTLMNACYP1A2CYP3A4CYP2C9
SCHEMBL20460397 0.79 RUNX1 (0.54) LMNARUNX1MAPK1AAK1KDM4E
Hydrochloric Acid SCHEMBL30880572 0.79 NPC1 (0.42) TRPV1SMN1; SMN2MEN1HTTKMT2A
SCHEMBL15129852 0.79 LMNA (0.68) TRPV1SMN1; SMN2MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486234-B2 PAPD5 inhibitors and methods of use thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-12-02 US disclosed
CN-119798159-A PAPD5 inhibitors and methods of use thereof 儿童医学中心公司 2025-04-11 CN disclosed
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION 2022-09-01 US disclosed
EP-3959197-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-03-02 EP disclosed
CN-113993848-A Inhibitors of PAPD5 and methods of use thereof 儿童医学中心公司 2022-01-28 CN disclosed
WO-2020219729-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-10-29 WO disclosed
WO-2020219729-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-10-29 WO disclosed
US-20120122923-A1 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
US-20120122923-A1 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
CN-101466706-A Bimolecules comprising peroxide derivatives, their synthesis and therapeutic use SANOFI AVENTIS (FR) 2009-06-24 CN disclosed
EP-2032561-A2 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES Sanofi-Aventis (FR) 2009-03-11 EP disclosed
WO-2007144487-A2 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES SANOFI-AVENTIS (FR) 2007-12-21 WO disclosed
CN-101035784-A New bicyclic antibiotics ACTELION PHARMACEUTICALS LTD (CH) 2007-09-12 CN disclosed
EP-1799676-A2 NEW BICYCLIC ANTIBIOTICS Actelion Pharmaceuticals Ltd. (CH) 2007-06-27 EP disclosed
WO-2006032466-A2 NEW BICYCLIC ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT TRPV1 4789/4885SMN1; SMN2 2702/4885MEN1 3400/4885
US-20120122923-A1 DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES DUOX2, DUOX1, CYP11B2 TRPV1 3291/4885SMN1; SMN2 2681/4885MEN1 3699/4885
US-12486234-B2 PAPD5 inhibitors and methods of use thereof POT1, PARP15, TERT TRPV1 4789/4885SMN1; SMN2 2702/4885MEN1 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.